Gastric neoplasm
Therapeutic area
Gastroenterology
Rare disease
No
- Definition
- A benign or malignant neoplasm involving the stomach.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Gastric neoplasm
- Therapeutic area
- Gastroenterology
- gastric neoplasm
- gastric neoplasm
- gastric tumor
- gastric tumour
- neoplasm of stomach
- neoplasm of the stomach
- stomach neoplasm
- stomach neoplasm (disease)
- stomach tumor
- stomach tumour
- tumor of stomach
- tumor of the stomach
- tumour of stomach
- tumour of the stomach
- Severity
- Severe
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0021085
- Parent condition
- MONDO:0004298
Related records
Broader conditions (10)
- Cancer or benign tumor
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Stomach disorder
Narrower conditions (61)
- Benign neoplasm of stomach
- Carcinoma in situ of fundus of stomach
- Carcinoma in situ of gastric body
- Carcinoma in situ of gastric cardia
- Carcinoma of stomach, salivary gland type
- Cardia cancer
- CTNNA1-related diffuse gastric and lobular breast cancer syndrome
- Diffuse gastric adenocarcinoma
- Diffuse gastric cancer
- Epstein-Barr virus-associated gastric carcinoma
- Familial gastric type 1 neuroendocrine tumor
- Gastric adenocarcinoma
- Gastric adenocarcinoma and proximal polyposis of the stomach
- Gastric adenoma
- Gastric adenosquamous carcinoma
- Gastric body carcinoma
- Gastric cancer
- Gastric carcinoma
- Gastric cardia adenocarcinoma
- Gastric cardia carcinoma
Trials (3,119)
- "Mechanisms and Biomarkers of Response and Resistance to Current Targeted Therapies in Gastric Cancer" (THERRES)
- "Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy
- "The Impact of Immunonutrition on Gut Microbiota-related Aspects in Colorectal Cancer and Gastric Cancer Patients"
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer
- 124I-FIAU Imaging in EBV and KSHV Associated Cancers
- 18F-FAPI PET/CT and MRI in Gastric Cancer
- 18F-FDG PET/CT in Gastric Cancer
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 3D Versus 2D Laparoscopic Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection
- 3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
- 4SCAR-CD44v6 T Cell Therapy Targeting Cancer
- 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
- 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- 68Ga-PMD22 PET/CT Examination Targeting CLDN18.2
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Approved drugs (6)
- Capecitabine
- Docetaxel
- Docetaxel anhydrous
- Ramucirumab
- Tislelizumab
- Trastuzumab
Drugs in development (56)
- Afatinib Phase 1
- AMG-337 Phase 2
- Axitinib Phase 1
- BMS-833923 Phase 1
- BMS-986310 Phase 2
- Camrelizumab Phase 3
- Cantuzumab ravtansine Phase 2
- Carboplatin Phase 2
- Catumaxomab Phase 3
- Cetuximab Phase 3
- Cisplatin Phase 3
- Durvalumab Phase 2
- Edotecarin Phase 2
- Entecavir Phase 2
- Epirubicin Phase 3
- Epirubicin hydrochloride Phase 3
- Etoposide Phase 3
- Everolimus Phase 3
- Fluorouracil Phase 3
- Fruquintinib Phase 3
Other linked drugs (4)
- Flumazenil
- Leniolisib
- Mosapride citrate
- Zolbetuximab